Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epithelium-On CXL for Keratoconus
NCT03245853Phase 4Completed
- Sponsor
- Comprehensive EyeCare of Central Ohio
- Start
- Jul 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Flavin mononucleotide in keratoconus, sponsored by Comprehensive EyeCare of Central Ohio. Primary endpoint: Maximum Keratometry at 12 months. Started Jul 2017; status: completed.
02
Drugs
Flavin mononucleotide
03
Conditions
keratoconus
Beyond the preview
Go deeper on NCT03245853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245853.